Alto Neuroscience Escapes Investor Drug Trial Suit, For Now
By Sydney Price · August 10, 2026, 6:07 PM EDT
Alto Neuroscience has escaped a shareholder suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, with a...
To view the full article, register now.